Neuropace Inc. Common Stock (NPCE)
Stock · NASDAQ · Health Care
$12.25as of 10/16/2026
Price chart
Active signals
NPCE Signal Track Record
How signals performed across all stocks →What NPCE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -0.5% | 50% | September 18, 2026 |
| Bollinger Band Breakout | 25 | +0.3% | 52% | July 6, 2026 |
| Bollinger Band Breakdown | 21 | +12.6% | 67% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +4.5% | 50% | August 11, 2026 |
| Any 20-session window (baseline) | -0.1% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable ac…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 220
- Website
- www.neuropace.com/
Fundamentals
- 1-day range
- $12.62$13
- Market cap
- $473.90M
- P/E (trailing)
- —
- P/E (forward)
- -58.76
- EPS (trailing)
- $-0.57
- Dividend yield
- —
- Beta
- 1.95
- Avg. volume
- 165.8K
How Neuropace Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Neuropace Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NPCENeuropace Inc. Common Stock$12.24▼ 4.23%Market cap $473.90MP/E —$9.22$19.6
- CERSCerus Corporation Common Stock$2.18▼ 3.54%Market cap $467.54MP/E —$1.38$3.47
- SIShoulder Innovations Inc. Common Stock$18.09▼ 1.52%Market cap $465.16MP/E —$10.92$24.6
- OFIXOrthofix Medical Inc. Common Stock (DE)$9.38▼ 2.19%Market cap $428.47MP/E —$8.5$16.99
- DCTHDelcath Systems Inc. Common Stock$14.08▼ 4.93%Market cap $534.05MP/E 962.21$8.12$17.42
- MOBIMobia Medical Inc. Common Stock$8.09▼ 2.65%Market cap $409.63MP/E —$8.16$15.29
- CLPTClearPoint Neuro Inc. Common Stock$9.07▼ 5.91%Market cap $408.45MP/E —$8.27$28.1
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NPCE Neuropace Inc. Common Stock | $473.90M | — | $12.24 | ▼ 4.23% | $9.22$19.6 |
| CERS Cerus Corporation Common Stock | $467.54M | — | $2.18 | ▼ 3.54% | $1.38$3.47 |
| SI Shoulder Innovations Inc. Common Stock | $465.16M | — | $18.09 | ▼ 1.52% | $10.92$24.6 |
| OFIX Orthofix Medical Inc. Common Stock (DE) | $428.47M | — | $9.38 | ▼ 2.19% | $8.5$16.99 |
| DCTH Delcath Systems Inc. Common Stock | $534.05M | 962.21 | $14.08 | ▼ 4.93% | $8.12$17.42 |
| MOBI Mobia Medical Inc. Common Stock | $409.63M | — | $8.09 | ▼ 2.65% | $8.16$15.29 |
| CLPT ClearPoint Neuro Inc. Common Stock | $408.45M | — | $9.07 | ▼ 5.91% | $8.27$28.1 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga · 9/18/2026
- This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · 9/18/2026
- Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18Benzinga · 9/18/2026
Insider Activity
Insider Actions →- Martha Morrell · September 24, 2026 · Tax Withholding335 @ $13.97
- Patrick F. Williams · September 20, 2026 · Tax Withholding1.2K @ $14.28
- Joel Becker · September 3, 2026 · Tax Withholding1.3K @ $14.75
- Martha Morrell · August 27, 2026 · Tax Withholding358 @ $14.13
- Joel Becker · August 27, 2026 · Tax Withholding1.1K @ $14.13
- Martha Morrell · June 24, 2026 · Tax Withholding335 @ $16.22
- Frank M. Fischer · June 19, 2026 · Grant1.5K @ $15.63
- Rakhi Kumar · June 19, 2026 · Grant989 @ $15.63
- Uri Geiger · June 19, 2026 · Grant789 @ $15.63
- Rakhi Kumar · June 5, 2026 · Grant5.4K
- Rakhi Kumar · June 5, 2026 · Grant2.9K
- Renee Ryan · June 5, 2026 · Grant5.4K
- Renee Ryan · June 5, 2026 · Grant2.9K
- Lisa Andrade · June 5, 2026 · Grant5.4K
- Lisa Andrade · June 5, 2026 · Grant2.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 25.95M
- Total value held
- $336.97M
- Institutional holders
- 108
- Unknown3.30M
- Unknown2.93M
- Unknown2.57M
- Unknown2.46M
- Unknown2.35M
- Unknown2.10M
- Unknown1.45M
- Unknown1.12M
- Unknown932.1K
- Unknown692.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating
Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.
Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating. Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.